Neurobiological and psychiatric consequences of child abuse and neglect
The effects of early‐life trauma and its consequences for the treatment of depression are reviewed. The prevalence and clinical sequelae of early sexual and physical abuse, neglect and parental loss are described. An overview of preclinical studies that help guide clinical research and practice is p...
Saved in:
Published in: | Developmental psychobiology Vol. 52; no. 7; pp. 671 - 690 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01-11-2010
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The effects of early‐life trauma and its consequences for the treatment of depression are reviewed. The prevalence and clinical sequelae of early sexual and physical abuse, neglect and parental loss are described. An overview of preclinical studies that help guide clinical research and practice is presented. Human clinical studies on the neurobiological consequences of early trauma are summarized. Moderating factors, such as genetic variation and sex differences, are discussed. The few current treatment outcome studies relevant to this research area are described. Guidance for the management of patients with depression and a history of child abuse and neglect are provided. Most patients who have experienced early traumatic experiences are likely best treated with a combination of psychotherapy and pharmacotherapy. This review is dedicated to the memory of Seymour Levine who pioneered the field of early experience research and to a considerable extent inspired the clinical studies described in this review. © 2010 Wiley Periodicals, Inc. Dev Psychobiol 52: 671–690, 2010. |
---|---|
Bibliography: | istex:850C66B163BAE1EF76ACFD3E34075CAB49C58532 Financial disclosures-Craighead, W. Edward: Dr. Craighead's research is funded by NIMH. He receives book royalties from John Wiley & Sons Publishers. He is a stockholder of NovaDel Pharma stock. He serves on the board of directors of Hugarheill, an Icelandic LLC. He is a Senior Fellow of the Emory Center for the Study of Law and Religion. Christine Heim: Dr. Heim has received or receives funding or fees from NIMH, NARSAD, ADAA, Center for Behavioral Neuroscience, CDC, Eli Lilly, Novartis, and CeNeRx. Charles B. Nemeroff: Scientific Advisory Board: AFSP; AstraZeneca; NARSAD, PharmaNeuroboost, CeNeRx; Stockholder or Equity: Corcept; Revaax; NovaDel Pharma; CeNeRx, PharmaNeuroboost, Mt. Cook Pharma; Board of Directors: American Foundation for Suicide Prevention (AFSP); George West Mental Health Foundation; NovaDel Pharma, Mt. Cook Pharma, Inc.; Patents: Method and devices for transdermal delivery of lithium (US 6,375,990 B1) Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001). ark:/67375/WNG-43X11RPT-D ArticleID:DEV20494 Financial disclosures—Craighead, W. Edward: Dr. Craighead's research is funded by NIMH. He receives book royalties from John Wiley & Sons Publishers. He is a stockholder of NovaDel Pharma stock. He serves on the board of directors of Hugarheill, an Icelandic LLC. He is a Senior Fellow of the Emory Center for the Study of Law and Religion. Christine Heim: Dr. Heim has received or receives funding or fees from NIMH, NARSAD, ADAA, Center for Behavioral Neuroscience, CDC, Eli Lilly, Novartis, and CeNeRx. Charles B. Nemeroff: Scientific Advisory Board: AFSP; AstraZeneca; NARSAD, PharmaNeuroboost, CeNeRx; Stockholder or Equity: Corcept; Revaax; NovaDel Pharma; CeNeRx, PharmaNeuroboost, Mt. Cook Pharma; Board of Directors: American Foundation for Suicide Prevention (AFSP); George West Mental Health Foundation; NovaDel Pharma, Mt. Cook Pharma, Inc.; Patents: Method and devices for transdermal delivery of lithium (US 6,375,990 B1) Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001). ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Feature-3 ObjectType-Review-1 |
ISSN: | 0012-1630 1098-2302 1098-2302 |
DOI: | 10.1002/dev.20494 |